Business Wire

StrongPoint’s Order Picking Solution Delivers Unprecedented Levels of Efficiency to Accelerate Grocers’ E-Commerce Capabilities

23.6.2021 09:00:00 EEST | Business Wire | Press release

Share

StrongPoint ASA, a leading European grocery retail solution provider, today announces its grocery e-commerce picking solution, designed specifically for grocery retailers looking for fast, hyper-efficient and scalable e-commerce logistics solutions. The Strongpoint solution suite delivers industry-leading efficiency rates with many in-store associates averaging ~240 items picked per labor hour across all product categories, compared with common industry standards of 60-65 items per hour.

Hosted on StrongPoint’s cloud-based SaaS e-commerce platform, the Order Picking solution helps retailers capitalize on the growing opportunity of online grocery, driving greater efficiency and higher productivity rates. It also reduces labor costs associated with the fulfillment of online orders, while enhancing customer convenience and protecting margins.

StrongPoint launched its first Order Picking solution more than 20 years ago. Since then, it has undergone countless iterations, changes and updates based on customer feedback over two decades of usage by thousands of pickers in multiple countries. A key benefit of StrongPoint’s cloud-based solution is that grocery retailers receive continuous updates as the team finds new opportunities to drive efficiency gains.

Since the start of the pandemic, Bain estimates adoption of online grocery in the US and Western Europe has accelerated between two and five years and this sustained demand is set to continue2. Despite the explosion in demand, both for grocery e-commerce and q-commerce, retailers have struggled to make online grocery profitable, with the high cost of labor hours allocated to picking and the fulfillment of e-commerce orders ebbing away at already squeezed margins.

StrongPoint’s solution was born out of 35+ years’ experience in responding to the rapidly evolving needs of leading grocery retailers across multiple European countries. Its grocery e-commerce Order Picking solution delivers unprecedented efficiencies compared to orders that are picked manually, by empowering staff with its proprietary software technology.

Many of StrongPoint’s grocery retail customers who are utilizing the full functionalities of the solution are able to reach average in-store picking rates of ~240 items per labor hour across all product categories, compared with a common industry standard of 60-65 items per labor hour when using traditional solutions. In addition, StrongPoint’s Order Picking solution averages 99.99% accuracy, making it on par with leading fully automated grocery fulfillment solutions.

Its hyper-efficient orchestration technology customizes the picking route for the store associate, creating the most effective order sequencing for picking, based on the unique layout and footprint of each store. Other standard features include picking by temperature zones, multiple solutions for age-restricted items and substitution options.

The solution, which can be deployed in large and small format settings with the option of using Zebra hardware devices for maximum efficiency, includes multi-zone and multi-order picking capabilities to drive even greater efficiencies. It can integrate with in-built store hardware, such as electronic shelf labels (ESLs), allowing store associates to “pick to light” to increase speed and order accuracy. In addition, there is the option of integrating a smart trolley that has been purpose-built for maximum ergonomic efficiency. Data inputs at each stage of the picking process – from preparing the trolley to the picking, weighing, and bagging of products – create a continuous feedback loop, so ergonomic improvements can be made to drive further efficiencies, speed and accuracy.

“We are proud to unveil our latest technology solution, specifically designed to help grocery retailers leverage their stores and cater to the exponential growth of e-commerce,” said Jacob Tveraabak, CEO at StrongPoint. “Having worked with grocery retailers for over three decades, we understand the importance of driving speed, efficiency and scalability across their operations in the stores – and that was intrinsic in how we developed the latest iteration of our grocery e-commerce Order Picking solution.”

-ENDS-

Notes to editors

StrongPoint is a retail technology company that provides solutions to make shops smarter, shopping experiences better and online grocery shopping more efficient.

With over 450 employees in Norway, Sweden, the Baltics and Spain and, together with a wide partner network, StrongPoint supports businesses in more than 20 countries.

StrongPoint is headquartered in Norway and is listed on the Oslo Stock Exchange.

For more information, visit https://www.strongpoint.com/


1 https://www.mwpvl.com/MWPVL_International_-_Micro_Fulfillment_Centers_-_Passing_Fad_or_Permanent_Market_Shift.pdf
2 https://www.bain.com/insights/the-next-five-years-in-online-grocery-snap-chart/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Catherine Seeds
Ketner Group Communications (US)
catherine@ketnergroup.com
512.947.4062

Sarah Cole
Fieldworks Marketing (UK)
Sarah.cole@fieldworksmarketing.co.uk
0845 034 5602

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release

Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release

WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release

Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye